Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/26
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsPRNewsWire • 10/27/26
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 10/23/26
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?Zacks Investment Research • 10/15/26
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And MoreSeeking Alpha • 10/02/26
Nektar Therapeutics Tumbles Despite Long-Term Benefit From Alopecia DrugInvestors Business Daily • 10/01/26
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026PRNewsWire • 10/01/26
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic DermatitisPRNewsWire • 09/30/26
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026PRNewsWire • 09/28/26
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisPRNewsWire • 08/25/26
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another ComingSeeking Alpha • 08/14/26
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in FocusZacks Investment Research • 08/14/26